RecruitingPhase 2NCT07289763

Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

Studying Primary membranous glomerulonephritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Intervention
SHR-2173 injection(drug)
Enrollment
75 target
Eligibility
18-75 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07289763 on ClinicalTrials.gov

Other trials for Primary membranous glomerulonephritis

Additional recruiting or active studies for the same condition.

See all trials for Primary membranous glomerulonephritis

← Back to all trials